drugset / Trial / NCT02547844
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
Phase 4
Completed
30 enrolled
Hospital Universitari Vall d'Hebron Research Institute
Gilead Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®.
Timeline
- Start
- 2015-09
- Primary completion
- 2016-10
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | — | — |
| Subject | Rilpivirine | Small molecule | — | — |
| Background | Tenofovir | Small molecule | — | — |
| Background | emtricitabine | Other / unclassified | — | — |
Indications
No indication recorded.